Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Carbon monoxide–induced metabolic switch in adipocytes improves insulin resistance in obese mice
Laura Braud, … , Roberta Foresti, Roberto Motterlini
Laura Braud, … , Roberta Foresti, Roberto Motterlini
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e123485. https://doi.org/10.1172/jci.insight.123485.
View: Text | PDF
Research Article Metabolism Therapeutics

Carbon monoxide–induced metabolic switch in adipocytes improves insulin resistance in obese mice

  • Text
  • PDF
Abstract

Obesity is characterized by accumulation of adipose tissue and is one the most important risk factors in the development of insulin resistance. Carbon monoxide–releasing (CO-releasing) molecules (CO-RMs) have been reported to improve the metabolic profile of obese mice, but the underlying mechanism remains poorly defined. Here, we show that oral administration of CORM-401 to obese mice fed a high-fat diet (HFD) resulted in a significant reduction in body weight gain, accompanied by a marked improvement in glucose homeostasis. We further unmasked an action we believe to be novel, by which CO accumulates in visceral adipose tissue and uncouples mitochondrial respiration in adipocytes, ultimately leading to a concomitant switch toward glycolysis. This was accompanied by enhanced systemic and adipose tissue insulin sensitivity, as indicated by a lower blood glucose and increased Akt phosphorylation. Our findings indicate that the transient uncoupling activity of CO elicited by repetitive administration of CORM-401 is associated with lower weight gain and increased insulin sensitivity during HFD. Thus, prototypic compounds that release CO could be investigated for developing promising insulin-sensitizing agents.

Authors

Laura Braud, Maria Pini, Lucie Muchova, Sylvie Manin, Hiroaki Kitagishi, Daigo Sawaki, Gabor Czibik, Julien Ternacle, Geneviève Derumeaux, Roberta Foresti, Roberto Motterlini

×

Figure 3

CO delivered by CORM-401 increases systemic and adipocytes insulin sensitivity both in vivo and in vitro.

Options: View larger image (or click on image) Download as PowerPoint
CO delivered by CORM-401 increases systemic and adipocytes insulin sensi...
CO content was measured in epidydimal white adipose tissue (eWAT) after oral gavage with PBS (CON), inactive CORM that does not release CO (iCORM, 30 mg/kg), or CORM-401 (30 mg/kg) (A). An ITT was performed in fasted mice 1 hour after oral gavage with PBS (CON), iCORM (30 mg/kg), or CORM-401 (30 mg/kg) (B), while blood glucose levels were measured at the times indicated (C) and represented by area under the curve (ITT AUC) (D). eWAT was evaluated for protein expression of total Akt and phosphorylated Akt assessed by Western blot (E and F). Intracellular CO level in 3T3-L1 adipocytes after CORM-401 exposure at 50 μM for 3 hours (G). Proteins were extracted from quiescent 3T3-L1 adipocytes after 3 hours exposure to PBS (CON), iCORM (50 μM), or CORM-401 (50 μM) (see protocol in H). Expression of total Akt and phosphorylated Akt was assessed by Western blot (I and J). Results are expressed as mean ± SEM. n = 4–6 mice per group (A); n = 10 mice per group (C and D); n = 8 mice per group (E and F); n = 3 in triplicates (G); n = 6 (I); n = 4 independent experiments (J). *P < 0.05 vs. control group (CON), #P < 0.05 vs. insulin, 1-way ANOVA with Fisher multiple comparison test. Values not designated with symbols are not statistically different.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts